FIELD: medicine.
SUBSTANCE: this invention is related to treatment of diseases characterized by failures of signal transmission along the MAP kinase path, and the patient is treated with injections of isohinilin-based compounds. The use of isohilinin-based compounds is similarly described as a method of melanoma treatment.
EFFECT: method of this invention is primarily used to treat cancer types related to RAF kinase mutations, especially of melanoma.
4 tbl, 76 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHTHALAZINES ELICITING ANGIOGENESIS INHIBITORY ACTIVITY | 1998 |
|
RU2207132C2 |
| STAUROSPORIN DERIVATIVES USED FOR TREATING ALVEOLAR RHABDOMYOBLASTOMA | 2006 |
|
RU2443421C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| ANTHRANILIC ACID AND THIOANTHRANILIC ACID N-ARYLAMIDES | 1999 |
|
RU2286338C2 |
| APPLICATION OF PYRIMIDYLAMINOBENZAMIDES FOR TREATMENT OF DISEASES SENSITIVE TO MODULATION OF KINASE Tie-2 ACTIVITY | 2006 |
|
RU2404776C2 |
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| PYRIMIDYLAMINOBENZAMIDE DERIVATIVES FOR NEUROFIBROMATOSIS | 2006 |
|
RU2450814C2 |
| ANNELATED AZAHETEROCYCLIC AMIDES, WHICH INCLUDE PYRIMIDINE FRAGMENT, METHOD OF OBTAINING AND THEIR APPLICATION | 2007 |
|
RU2345996C1 |
| IMIDAZOPYRIDINE IAP INHIBITORS | 2007 |
|
RU2466131C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
